Valuation: Satellos Bioscience Inc.

Market Cap 198M 172M 160M 147M 277M 18.87B 282M 1.88B 739M 9.4B 743M 726M 31.13B P/E 2026 *
-5.69x
P/E 2027 * -6.07x
Enterprise Value 104M 90.34M 84.08M 77.25M 146M 9.93B 148M 990M 389M 4.95B 391M 382M 16.39B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
93.52%
Yield 2026 *
-
Yield 2027 * -
1 day+5.11%
1 week+2.26%
Current month+31.33%
1 month+31.33%
3 months+30.23%
6 months-9.50%
Current year+76.77%
1 week 13
Extreme 13
14
1 month 10.17
Extreme 10.17
14.99
Current year 7.67
Extreme 7.67
18.98
1 year 6.36
Extreme 6.36
18.98
3 years 3.48
Extreme 3.48
18.98
5 years 2.58
Extreme 2.58
22.8
10 years 2.58
Extreme 2.58
22.8
Manager TitleAgeSince
Chief Executive Officer 70 01/03/2018
Chief Tech/Sci/R&D Officer - 01/05/2018
Director of Finance/CFO - 01/09/2023
Director TitleAgeSince
Chairman 59 01/07/2018
Director/Board Member 50 01/03/2018
Director/Board Member 70 01/07/2012
Date Insider Type Main position Quantity % Market Cap.
14/7/26 Buy

Director

2,575 0.0124%
14/7/26 Buy

Director

939 0.0045%
14/7/26 Buy

Director

370 0.0018%
Change 5-day change 1-year change 3-year change Capi.($)
+5.11%+2.26%+112.12%+174.51% 198M
+2.35%+0.77%+29.92%+85.38% 55.23B
-0.21%-6.52%+42.39%+64.10% 53.75B
-2.44%-1.61%-17.69%-15.68% 23.48B
-2.85%-8.20%-6.26%+361.83% 22B
+2.49%-1.27%+15.99%-10.53% 19.78B
+0.79%-2.39%+26.99%-31.34% 17.44B
+0.58%-7.23%+24.50%+519.07% 14.66B
-5.25%-4.71%+43.89%+167.15% 14.07B
+3.41%-7.83%+161.76%+284.91% 13.02B
Average +0.40%-1.71%+43.36%+159.94% 23.36B
Weighted average by Cap. +0.18%+0.09%+31.12%+122.85%

Financials

2026 *2027 *
Net sales - -
Net income -48.32M -41.92M -39.02M -35.85M -67.73M -4.61B -68.83M -460M -181M -2.3B -181M -177M -7.61B -56.57M -49.07M -45.67M -41.96M -79.29M -5.4B -80.57M -538M -211M -2.69B -212M -208M -8.9B
Net Debt -93.65M -81.24M -75.61M -69.47M -131M -8.93B -133M -891M -350M -4.45B -352M -344M -14.74B -111M -96.59M -89.9M -82.6M -156M -10.62B -159M -1.06B -416M -5.29B -418M -409M -17.53B
Logo Satellos Bioscience Inc.
Satellos Bioscience Inc. is a Canada-based clinical-stage drug development company. The Company is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration. SAT-3247 targets AAK1, a key protein that has identified as capable of replacing the signal normally provided by dystrophin in muscle stem cells to effect repair and regeneration. It is also leveraging its proprietary discovery platform MyoReGenX to identify additional muscle diseases or injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and represent future clinical development opportunities. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process.
Employees
20
Date Price Change Volume
31/07/26 CA$14.00 +5.11% 8,740
30/07/26 CA$13.32 +1.91% 740
29/07/26 CA$13.07 -2.17% 18,400
28/07/26 CA$13.36 +0.45% 5,726
27/07/26 CA$13.30 -4.66% 23,688
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
13.32CAD
Average target price
17.67CAD
Spread / Average Target
+32.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MSCL Stock